Business Wire

Ricardo Air Quality and Economic Expertise to Help European Commission Reduce Hundreds of Thousands of Premature Deaths From Air Pollution

15.11.2022 03:01:00 EET | Business Wire | Press release

Share

Ricardo, a global strategic environmental and engineering consulting company, has significantly contributed to the European Commission’s revision of the Ambient Air Quality Directive which sets air quality standards for European Union Member States. This Directive underpins the improvement of air quality to reduce the 300,000 premature deaths a year and a significant number of noncommunicable diseases such as asthma, cardiovascular problems and lung cancer, which are still attributed to air pollution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221114005544/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Smog in the city of Milan, Italy (Photo: Business Wire)

Led by Ricardo, a team of air quality experts, including IIASA, Met.No, VITO and Trinomics, carried out an impact assessment into options to revise the legislation. Using scenario modelling to 2050, Ricardo considered what the potential impacts of the new air quality standards could be in relation to public health, the environment and business. Ricardo provided economic expertise to the impact assessment which shows that the benefits of the proposed revision for society far outweigh the costs. The main benefits expected are related to health: including reduced mortality and morbidity, reduced healthcare expenditure, reduced absence from work due to illness and increased productivity at work. Additionally, key benefits for the environment include reduced ozone-related crop yield losses.

A further study, also led by Ricardo, set out suggestions to improve support for local authorities in achieving cleaner air through strengthening air quality monitoring, modelling and plans.

Dr Beth Conlan, Technical Director – Air Quality at Ricardo said: “Ricardo has the longest-established specialist air quality team in the world and, with over 130 experts, one of the largest, and this is reflected in the UK’s position as a world-leader in air quality expertise. As our corporate mission is to create a safe and sustainable world, we are honoured that the European Commission chose to entrust this seminal project to us, which will significantly reduce deaths, improve people’s quality of life and public health in general. Legislation really does push forward change and, in my thirty years of working in this sector, this regulatory revision is likely to be the most far reaching and valuable in terms of improving air quality.”

Ricardo has provided expertise to the European Union (EU) in air quality and climate change since the 1990s, supporting the EU’s drive to lower emissions, through the Green Deal, and air quality directives – the last one of which was enacted in 2008. Ricardo’s air quality team has very well-established capability in air quality assessment and management practice. It was this capability, together with Ricardo’s economic expertise and proven track record in successfully delivering co-beneficial air quality and climate change programmes for the European Commission that led to the Ricardo-managed air quality team working on this project.

In the UK, Ricardo’s air quality expertise is helping the national Government shape strategies that offer routes to delivering national emissions reduction commitments such as the UK’s Clean Air Strategy, the National Air Pollution Control Plan, National Emission Ceilings targets, Environment Act Air Quality targets, and the UK’s net zero strategy, as well as international objectives through the Gothenburg Protocol.

Ends

About Ricardo

Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contacts:
Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye